Sintilimab
- Generic Name
- Sintilimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2072873-06-2
- Unique Ingredient Identifier
- 8FU7FQ8UPK
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Platinum-Containing Chemotherapy.
- Conditions
- Interventions
- First Posted Date
- 2019-03-05
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- Xin-Hua Xu
- Target Recruit Count
- 70
- Registration Number
- NCT03863483
- Locations
- 🇨🇳
Department of Medical Oncology, Central Hospital of Yichang City, the First Clinical Medical College of Three Gorges University, Yichang, Hubei, China
A Study of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2019-02-05
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- Xin-Hua Xu
- Target Recruit Count
- 76
- Registration Number
- NCT03830411
- Locations
- 🇨🇳
Department of Medical Oncology, Central Hospital of Yichang City, the First Clinical Medical College of Three Gorges University, Yichang, Hubei, China
Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL
- First Posted Date
- 2019-01-29
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- Huiqiang Huang
- Target Recruit Count
- 40
- Registration Number
- NCT03820596
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, China
🇨🇳Department of hematology department, Nanfang hospital, Guangzhou, Guangdong, China
🇨🇳Guangdong General Hospital; Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients
- Conditions
- Interventions
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2022-07-13
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 29
- Registration Number
- NCT03812549
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure
- Conditions
- Interventions
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 492
- Registration Number
- NCT03802240
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.
- First Posted Date
- 2019-01-07
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 595
- Registration Number
- NCT03794440
- Locations
- 🇨🇳
Hospital of Fudan University, Shanghai, Shanghai, China
First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors
- First Posted Date
- 2018-11-29
- Last Posted Date
- 2023-02-22
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT03758001
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 650
- Registration Number
- NCT03745170
- Locations
- 🇨🇳
The Fifth Medical Center,Chinese PLA General Hospital, Beijing, Beijing, China
Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2018-10-09
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 425
- Registration Number
- NCT03700476
- Locations
- 🇨🇳
Panyu central hospital, Guangzhou, Guangdong, China
🇨🇳Xijing Hospital, Fourth Military Medical University, Xi'an, Shanxi, China
🇨🇳West China Hospital, Sichuan University, Chengdu, Sichuan, China
Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC
- Conditions
- Interventions
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 357
- Registration Number
- NCT03629925
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.